The failure of the prior trial was suspected, and I believe it, due to a refractory response by overdosing the inner ear with too frequent administrations of the drug, and then testing for effect too soon. I bet even those candidates of the phase IIa trial though would, if checked on now, show some improvement.
Animal research has shown that natural cochlear hair cell regeneration and resultant hearing restoration is very real, we mammals just don't have the natural cellular signaling to redifferentiate those base cells - small molecule drugs like FX322 do exactly that. I am optimistic they'll eventually find the right dosing regimen to see reliable and optimal clinical effect, and it will be a seismic advance in medicine.
The failure of the prior trial was suspected, and I believe it, due to a refractory response by overdosing the inner ear with too frequent administrations of the drug, and then testing for effect too soon. I bet even those candidates of the phase IIa trial though would, if checked on now, show some improvement.
Animal research has shown that natural cochlear hair cell regeneration and resultant hearing restoration is very real, we mammals just don't have the natural cellular signaling to redifferentiate those base cells - small molecule drugs like FX322 do exactly that. I am optimistic they'll eventually find the right dosing regimen to see reliable and optimal clinical effect, and it will be a seismic advance in medicine.